Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Summary

The purpose of this research study is to find out more about the combination of RAD001 and sorafenib such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating neuroendocrine tumors.

Timeline

Start

2009-07

Primary completion

2013-03

Completion

2013-03

Publications

• Results Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke MH. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol. 2013 May;71(5):1241-6. doi: 10.1007/s00280-013-2118-9. Epub 2013 Mar 9.

Drugs

Indications